📊 ELV Key Takeaways
Is ELV a Good Investment? Thesis Analysis
Elevance Health demonstrates solid financial fundamentals with strong revenue growth of 12.5% YoY and robust cash generation, supported by healthy liquidity metrics and manageable leverage. However, flat net income growth and modest profit margins (2.8% net, 3.6% operating) reflect the competitive nature of the health insurance sector and rising cost pressures.
Why Buy ELV? Key Strengths
- Strong revenue growth of 12.5% YoY demonstrates market expansion and pricing power
- Solid cash flow generation with $3.2B free cash flow and 1.6% FCF margin providing financial flexibility
- Conservative leverage with 0.73x debt-to-equity and strong interest coverage of 8.5x indicating manageable debt servicing
- Healthy liquidity position with 1.54x current ratio and $9.5B in cash equivalents
ELV Investment Risks to Consider
- Flat net income growth (0.0% YoY) despite 12.5% revenue growth suggests margin compression and rising operational costs
- Low profit margins (2.8% net, 3.6% operating) leave limited cushion for adverse business conditions or increased claims
- High long-term debt of $31.9B relative to operating income creates refinancing risk and limits financial flexibility
- Diluted EPS declined 1.8% YoY despite revenue growth, indicating shareholder value erosion from share issuance or margin pressure
Key Metrics to Watch
- Net margin trend - critical to monitor for continued compression or stabilization
- Operating cash flow sustainability - must maintain $4B+ annually to support debt service and capital needs
- Medical loss ratio and claims management efficiency - primary driver of profitability in insurance sector
- Debt-to-EBITDA ratio - monitor to ensure leverage remains manageable amid market pressures
ELV Financial Metrics
💡 AI Analyst Insight
The relatively thin 1.6% FCF margin may limit capital allocation flexibility.
ELV Profitability Ratios
ELV vs Healthcare Sector
How Elevance Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELV Overvalued or Undervalued?
Based on fundamental analysis, Elevance Health, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELV Balance Sheet & Liquidity
ELV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Elevance Health, Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $25.22 reflects profitable operations.
ELV Growth Metrics (YoY)
ELV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $45.1B | $1.0B | $4.36 |
| Q2 2025 | $43.9B | $1.7B | $7.72 |
| Q1 2025 | $42.6B | $2.2B | $9.59 |
| Q3 2024 | $42.8B | $1.0B | $4.36 |
| Q2 2024 | $43.7B | $1.9B | $7.79 |
| Q1 2024 | $42.2B | $2.0B | $8.30 |
| Q3 2023 | $39.9B | $1.3B | $5.45 |
| Q2 2023 | $38.6B | $1.6B | $6.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELV Capital Allocation
ELV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Elevance Health, Inc. (CIK: 0001156039)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELV
What is the AI rating for ELV?
Elevance Health, Inc. (ELV) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELV's key strengths?
Claude: Strong revenue growth of 12.5% YoY demonstrates market expansion and pricing power. Solid cash flow generation with $3.2B free cash flow and 1.6% FCF margin providing financial flexibility.
What are the risks of investing in ELV?
Claude: Flat net income growth (0.0% YoY) despite 12.5% revenue growth suggests margin compression and rising operational costs. Low profit margins (2.8% net, 3.6% operating) leave limited cushion for adverse business conditions or increased claims.
What is ELV's revenue and growth?
Elevance Health, Inc. reported revenue of $199.1B.
Does ELV pay dividends?
Elevance Health, Inc. pays dividends, with $1,529.0M distributed to shareholders in the trailing twelve months.
Where can I find ELV SEC filings?
Official SEC filings for Elevance Health, Inc. (CIK: 0001156039) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELV's EPS?
Elevance Health, Inc. has a diluted EPS of $25.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELV a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Elevance Health, Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ELV stock overvalued or undervalued?
Valuation metrics for ELV: ROE of 12.9% (sector avg: 15%), net margin of 2.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELV stock in 2026?
Our dual AI analysis gives Elevance Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELV's free cash flow?
Elevance Health, Inc.'s operating cash flow is $4.3B, with capital expenditures of $1.1B. FCF margin is 1.6%.
How does ELV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.8% (avg: 12%), ROE 12.9% (avg: 15%), current ratio 1.54 (avg: 2).